Intellia Therapeutics Inc [NTLA] stock is trading at $10.29, down -4.10%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The NTLA shares have lost -5.25% over the last week, with a monthly amount drifted -18.53%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Intellia Therapeutics Inc [NASDAQ: NTLA] stock has seen the most recent analyst activity on April 21, 2025, when Wolfe Research upgraded its rating to a Outperform but kept the price target unchanged to $21 for it. Previously, H.C. Wainwright started tracking the stock with Buy rating on March 05, 2025, and set its price target to $30. On February 28, 2025, downgrade downgraded it’s rating to Neutral and revised its price target to $13 on the stock. Goldman downgraded its rating to a Sell but stick to its price target of $9 on February 28, 2025. Morgan Stanley downgraded its rating to a Equal-Weight and reduced its price target to $11 on January 27, 2025. Goldman downgraded its rating to Neutral for this stock on February 23, 2024, and downed its price target to $32. In a note dated February 15, 2024, Wolfe Research initiated an Peer Perform rating.
Intellia Therapeutics Inc [NTLA] stock has fluctuated between $5.90 and $24.16 over the past year. Currently, Wall Street analysts expect the stock to reach $16.33 within the next 12 months. Intellia Therapeutics Inc [NASDAQ: NTLA] shares were valued at $10.29 at the most recent close of the market. An investor can expect a potential return of 58.7% based on the average NTLA price forecast.
Analyzing the NTLA fundamentals
Intellia Therapeutics Inc [NASDAQ:NTLA] reported sales of 52.86M for the trailing twelve months, which represents a growth of 104.76%. Gross Profit Margin for this corporation currently stands at 0.9% with Operating Profit Margin at -9.69%, Pretax Profit Margin comes in at -9.08%, and Net Profit Margin reading is -9.08%. To continue investigating profitability, this company’s Return on Assets is posted at -0.53, Equity is -0.58 and Total Capital is -0.64. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.14.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 10.04 points at the first support level, and at 9.78 for the second support level. However, for the 1st resistance point, the stock is sitting at 10.63, and for the 2nd resistance point, it is at 10.97.
Ratios To Look Out For
For context, Intellia Therapeutics Inc’s Current Ratio is 5.19. Also, the Quick Ratio is 5.19, while the Cash Ratio stands at 1.64. Considering the valuation of this stock, the price to sales ratio is 20.90, the price to book ratio is 1.52.
Transactions by insiders
Recent insider trading involved Dulac Edward J III, EVP, Chief Financial Officer, that happened on Jul 23 ’25 when 7462.0 shares were sold. EVP, Chief Technical Officer, Clark Eliana completed a deal on Jul 01 ’25 to sell 1022.0 shares. Meanwhile, VP, Chief Accounting Officer Dube Michael P sold 2503.0 shares on Jul 02 ’25.
